Navigation Links
Hospira Expands Board of Directors
Date:3/9/2009

LAKE FOREST, Ill., March 9 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, announced today that Heino von Prondzynski has been elected to the company's board of directors. Von Prondzynski brings strong executive management and diverse global experience from leadership positions held at multinational healthcare companies. The addition of von Prondzynski expands Hospira's board to 10 directors, of whom nine are independent.

"Heino has an impressive track record of achievement in the healthcare industry and significant experience in delivering global growth and expansion," said Christopher B. Begley, chairman and chief executive officer. "His interest in talent development and passion for driving product innovation also make him an excellent and complementary addition to the Hospira board."

Von Prondzynski, 59, served as chief executive officer of Roche Diagnostics and as a member of the executive committee of F. Hoffman-La Roche Ltd. from early 2000 to 2005, retiring from Roche at the end of 2006. While at Roche, he brought Roche Diagnostics, which included diabetes, near-patient testing, centralized diagnostics and applied science to global market leadership and record industry-standard profitability ratios. He also drove significant growth through an expansion of the molecular diagnostics portfolio and entrance into the blood-screening market. From 1996 to 2000, von Prondzynski held several executive positions, including president of its vaccine business, at Chiron Corporation, a multinational firm that develops biopharmaceuticals, vaccines and blood-testing products. Earlier in his career, von Prondzynski held sales and marketing and general management positions at Bayer A.G.

Von Prondzynski is on the boards of Koninklijke Philips Electronics N.V. (Royal Philips Electronics Inc.), Qiagen N.V., BB Medtech A.G. and Epigenomics A.G.

Born in Germany, now living in Switzerland, von Prondzynski studied mathematics, geography and history at Westfalische Wilhelms University of Munster in Germany.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
2. Hospira to Present at the Credit Suisse Phoenix Health Care Conference on November 13
3. Hospira Reports Third-Quarter 2007 Results
4. Hospira to Present at the JPMorgan 26th Annual Healthcare Conference on January 9
5. Hospira Hosts Conference Call for Fourth-Quarter 2007 Results and 2008 Projections
6. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
7. Hospira Launches Generic Irinotecan Injection
8. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
9. Hospira to Present at the Bear Stearns 10th Annual London Healthcare Conference on March 13
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Hospira Acquires Sculptor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... of African American/Black students who want to become physicians. PMF also provides a ... as physicians in the Oakland/San Francisco Northern California, Bay Area. PMF’s mission is ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... Marc Philpart, senior director at PolicyLink, will be the keynote speaker at its ... Boys and Men of Color Framework, which develops comprehensive strategies to create and ...
(Date:2/21/2017)... ... ... Ray Insurance Agencies, a Dallas area firm providing asset protection services and ... six month charity event aimed at raising local support and donations that will be ... deadliest diseases in America; more than 7.5 million people die from cancer related disorders ...
(Date:2/21/2017)... ... February 21, 2017 , ... Each February ... History Month (officially African American History Month ). This month-long ... of a diverse race of people, but also the opportunity to examine the ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... MELBOURNE, Australia , Feb. 21, 2017  IBM (NYSE: ... IBM Watson,s ability to detect abnormalities of the eye,s retina. ... trained a research version of Watson to recognize abnormalities in ... insights and speed in their early identification of patients who ... glaucoma, a leading cause of blindness in the developed world. ...
(Date:2/21/2017)... , Feb. 21, 2017 Medical Oxygen ... report: http://www.reportlinker.com/p04711311-summary/view-report.html Medical oxygen concentrators ... other respiratory diseases. Patients having low level of ... oxygen concentrators. Oxygen concentrators are to be used ... the counter. Medical oxygen concentrators work either on ...
(Date:2/21/2017)... , Feb. 21, 2017   BeyondSpring Pharmaceuticals ... the development of innovative immuno-oncology cancer therapies, today ... data from its Phase 2 trial of BeyondSpring,s ... treatment of non-small cell lung cancer (NSCLC) with ... this year,s ASCO-SITC Clinical Immuno-Oncology Symposium in ...
Breaking Medicine Technology: